Cite
HARVARD Citation
Guo, Y. et al. (2019). Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial. Annals of oncology. pp. 1831-1839. [Online].